glp 1 news today glp-1 obesity drug updates New research is challenging long-held assumptions about GLP-1 drugs like Ozempic and
Description
EMPA-KIDNEY (Empagliflozin in Patients with Chronic Kidney Disease) showed that in patients with chronic kidney disease, empagliflozin leads to a lower risk of progression of kidney disease [29]
One number may cover the clinical visit and prescription support only
The primary competitive variable is not pricing but clinical differentiation through head-to-head efficacy comparisons and outcomes trial results
doi: 10.1111/j.1463-1326.2009.01194.x
Structural insights into the activation of GLP-1R by a small molecule agonist
